![Michael C. Chen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Career history of Michael C. Chen
Former positions of Michael C. Chen
Companies | Position | Start | End |
---|---|---|---|
EpiCept Corp.
![]() EpiCept Corp. Pharmaceuticals: MajorHealth Technology EpiCept Corp. is a pharmaceutical company, which focuses on the clinical development and commercialization of pharmaceutical products for the treatment of cancer and pain. The company focuses on analgesics targeting peripheral nerve receptors and cancer therapies. Its lead product Ceplene, is used concomitantly with low-dose interleukin-2, is intended as remission maintenance therapy in the treatment of acute myeloid leukemia for adult patients. The company's other oncology compounds include AmiKet, a late-stage pain product candidate for the treatment of peripheral neuropathies, and two other oncology compounds in clinical development, that that were discovered using in-house technology and have been shown to act as vascular disruption agents in solid tumors. EpiCept was founded in March 1993 and is headquartered in Tarrytown, NY. | Corporate Officer/Principal | 2006-04-30 | 2010-01-07 |
JOHNSON & JOHNSON | Corporate Officer/Principal | 1994-12-31 | 2003-12-31 |
Lundbeck Research USA, Inc.
![]() Lundbeck Research USA, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Research USA, Inc. develops pharmaceutical products and information to the medical community. The firm engages in the drug discovery aimed at treating central nervous system diseases by designing small molecule therapeutics. The company was founded in 1990 and is headquartered in Paramus, NJ. | Corporate Officer/Principal | 1992-12-31 | 1994-12-31 |
Ciba-Geigy AG
![]() Ciba-Geigy AG Pharmaceuticals: MajorHealth Technology Ciba-Geigy AG was manufacturing pharmaceuticals. The company was merged with Sandoz Ltd. to create Novartis AG. The company was founded in 1884 and was headquartered in Basle, Switzerland. | Corporate Officer/Principal | 1984-12-31 | 1992-12-31 |
Spyglass Consulting Group | Sales & Marketing | - | - |
Training of Michael C. Chen
Harvard University | Masters Business Admin |
Cornell University | Undergraduate Degree |
Statistics
International
United States | 7 |
Switzerland | 2 |
Operational
Corporate Officer/Principal | 4 |
Masters Business Admin | 1 |
Undergraduate Degree | 1 |
Sectoral
Health Technology | 5 |
Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
JOHNSON & JOHNSON | Health Technology |
Private companies | 4 |
---|---|
Lundbeck Research USA, Inc.
![]() Lundbeck Research USA, Inc. Pharmaceuticals: MajorHealth Technology Lundbeck Research USA, Inc. develops pharmaceutical products and information to the medical community. The firm engages in the drug discovery aimed at treating central nervous system diseases by designing small molecule therapeutics. The company was founded in 1990 and is headquartered in Paramus, NJ. | Health Technology |
Ciba-Geigy AG
![]() Ciba-Geigy AG Pharmaceuticals: MajorHealth Technology Ciba-Geigy AG was manufacturing pharmaceuticals. The company was merged with Sandoz Ltd. to create Novartis AG. The company was founded in 1884 and was headquartered in Basle, Switzerland. | Health Technology |
EpiCept Corp.
![]() EpiCept Corp. Pharmaceuticals: MajorHealth Technology EpiCept Corp. is a pharmaceutical company, which focuses on the clinical development and commercialization of pharmaceutical products for the treatment of cancer and pain. The company focuses on analgesics targeting peripheral nerve receptors and cancer therapies. Its lead product Ceplene, is used concomitantly with low-dose interleukin-2, is intended as remission maintenance therapy in the treatment of acute myeloid leukemia for adult patients. The company's other oncology compounds include AmiKet, a late-stage pain product candidate for the treatment of peripheral neuropathies, and two other oncology compounds in clinical development, that that were discovered using in-house technology and have been shown to act as vascular disruption agents in solid tumors. EpiCept was founded in March 1993 and is headquartered in Tarrytown, NY. | Health Technology |
Spyglass Consulting Group |
- Stock Market
- Insiders
- Michael C. Chen
- Experience